Efficacy of theracal as pulp capping material in permanent dentition: a systematic review and meta-analysis Authors: Maged Ahmed Mohamed, Rim Waly, Shahd Mahmoud, Asawer Ahmed Fayyad, Amr Azab, Rasha A Alamoush, Dina Abozaid Published: 2026 ABSTRACT AbstractBackgroundVital pulp therapy (VPT) aims to preserve pulp vitality through minimally invasive approaches, including indirect pulp capping (IPC), direct pulp capping (DPC), and pulpotomy. TheraCal LC, a light-cured resin-modified calcium silicate material, is widely used as a pulp-capping agent due to its favorable handling characteristics and bioactive properties. However, its clinical and radiographic efficacy remains insufficiently documented.ObjectiveThis systematic review and meta-analysis evaluated the effectiveness of TheraCal LC in IPC and DPC procedures and compared its performance with other pulp-capping materials, including mineral trioxide aggregate (MTA), calcium hydroxide, and Biodentine.MethodsA comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to August 2025. Randomized controlled trials assessing TheraCal LC in IPC or DPC of permanent teeth were included. Study selection, data extraction, and risk of bias assessment (ROB-2) were performed independently by multiple reviewers. Meta-analyses were conducted using random-effects models, with subgroup analyses based on follow-up duration.ResultsFrom 606 records identified across four databases, 11 clinical studies published between 2015 and 2025 met the inclusion criteria. These studies compared TheraCal LC with calcium hydroxide, Biodentine, and MTA in IPC and DPC. TheraCal LC demonstrated comparable clinical success rates to other materials, with consistently low pain scores and satisfactory dentin bridge formation during follow-up periods of 6–36 months. Risk of bias assessment indicated that most studies presented some concerns, primarily related to randomization and selective reporting, although overall methodological quality was acceptable.ConclusionsTheraCal LC represents a viable alternative to MTA, calcium hydroxide, and Biodentine for direct and indirect pulp capping in permanent teeth.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-026-09008-9.Keywords: TheraCal, Vital pulp therapy, Pulp capping, Calcium silicate, Systematic review, Meta-analysis Introduction Preservation of pulp vitality through conservative interventions is a cornerstone of modern endodontics, particularly in the management of teeth affected by deep carious lesions or traumatic pulp exposures. Vital pulp therapy (VPT) encompasses minimally invasive procedures such as indirect pulp treatment (IPT), direct pulp capping (DPC), and pulpotomy, all of which aim to sustain pulp health and promote reparative dentinogenesis [1]. Historically, calcium hydroxide has been regarded as the gold standard for pulp-capping procedures due to its well-established biocompatibility and ability to stimulate reparative dentin formation via alkaline pH and calcium ion release [2]. Nevertheless, calcium hydroxide presents notable limitations, including high solubility, poor adhesion, and progressive dissolution over time, which often result in tunnel-like defects within the induced dentin bridges [3]. These limitations have prompted extensive research into alternative biomaterials with enhanced bioactivity and superior physicochemical properties. Mineral trioxide aggregate (MTA), a calcium silicate–based cement, has emerged as a promising substitute, offering improved sealing ability, greater radiopacity, and superior biocompatibility compared with calcium hydroxide [4]. Nevertheless, conventional MTA presents notable clinical limitations, including prolonged setting times (initial setting time approximately 17 ± 2 min; final setting time 241 ± 6 min), challenging manipulation, risk of tooth discoloration, and handling difficulties that compromise its clinical feasibility, particularly in pediatric populations [5, 6]. In response to the limitations of conventional MTA, a new generation of resin-modified calcium silicate materials was developed. TheraCal LC, a light-cured, hydrophilic resin-modified calcium silicate liner, represents a significant advancement in pulp-capping technology. Unlike conventional MTA, TheraCal LC’s light-polymerizable formulation enables immediate setting and shorter treatment times, thereby enhancing clinical handling and improving patient cooperation [7]. The proprietary hydrophilic resin formulation of TheraCal LC incorporates tricalcium and dicalcium silicate particles suspended within a hydrophilic monomer matrix. Upon hydration, this composition releases substantial levels of calcium and hydroxide ions, generating an alkaline microenvironment that supports pulp healing and stimulates reparative dentinogenesis [7]. Comparative studies have shown that TheraCal LC releases higher concentrations of calcium ions than ProRoot MTA and conventional calcium hydroxide, while exhibiting significantly lower solubility and reduced water absorption. These properties contribute to its enhanced stability and sustained bioactivity in clinical applications [8]. The bioactive properties of TheraCal LC include induction of dentin bridge formation, stimulation of reparative dentinogenesis through odontoblastic activation, and promotion of apatite formation with subsequent hydroxyapatite deposition [9]. Multiple clinical and radiographic investigations have assessed its efficacy in both direct and indirect pulp-capping procedures across diverse patient populations and follow-up intervals. Although individual studies have reported promising clinical and radiographic success rates ranging from 85.7% to 100%, a comprehensive synthesis of the available evidence regarding the overall effectiveness of TheraCal LC as a pulp-capping agent is lacking in the current literature [2, 3]. Given the evolving landscape of biomaterials in contemporary vital pulp therapy and the clinical advantages attributed to TheraCal LC over conventional materials, this systematic review and meta-analysis was undertaken to provide a comprehensive, evidence-based synthesis of randomized controlled trials and prospective clinical studies evaluating TheraCal LC in pulp-capping procedures. The objectives of this review were to critically appraise the methodological quality of included studies, elucidate the clinical and radiographic success rates of TheraCal LC, assess its comparative effectiveness against alternative capping materials (calcium hydroxide, MTA, and Biodentine), and determine its relative efficacy in both direct and indirect pulp capping of permanent teeth. Such systematic evaluation is essential to inform evidence-based clinical decision-making, optimize material selection in vital pulp therapy protocols, and identify priorities for future high-quality clinical research focusing on long-term outcomes. Methods Study design and registration This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions [10, 11]. The study protocol was prospectively registered in the PROSPERO database (registration number: CRD420251252089), ensuring transparency and methodological rigor. Literature search strategy and data sources A comprehensive electronic literature search was conducted on August 8, 2025, across four databases: PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials. The search strategy combined the following keywords and their synonyms: pulp capping, TheraCal, and pulp therapy. Detailed database-specific search strategies are provided in Supplementary Table S1. Two reviewers (M.M. and S.M.) independently performed the search. To ensure completeness, reference lists of eligible studies and relevant systematic reviews were manually screened for additional randomized controlled trials (RCTs). Duplicate records were identified and removed using EndNote X8 and Rayyan [12]. Study selection and eligibility criteria (PICO) Study screening was performed independently by two reviewers (M.M. and S.M.) in two sequential stages: initial title and abstract screening followed by full-text assessment. Any discrepancies were resolved through discussion with a third reviewer (D.A.). The PICO framework and exclusion criteria applied in this study are summarized in Table 1. Table 1PICO and exclusion criteria used in this studyPopulationHuman studies involving permanent teeth with vital pulp undergoing direct pulp capping (DPC) or indirect pulp capping (IPC).InterventionUse of TheraCal (TheraCal LC or TheraCal PT, if applicable) as a pulp-capping material.ComparatorOther pulp-capping materials, including calcium hydroxide, mineral trioxide aggregate (MTA), Biodentine, resin-modified calcium silicate materials, no treatment, or placebo (if applicable).OutcomesPrimary outcomeClinical and/or radiographic success rate.Secondary outcomesDentin bridge formation, postoperative pain, pulp inflammation or necrosis.Study DesignRandomized controlled trials (RCTs).Exclusion Criteria• Animal studies.• In vitro or ex vivo studies.• Non-randomized clinical trials.• Prospective and retrospective cohort studies.• Case–control studies.• Reviews, editorials, and letters.• Studies not evaluating TheraCal as a pulp-capping agent. PICO and exclusion criteria used in this study Primary outcome Clinical and/or radiographic success rate. Secondary outcomes Dentin bridge formation, postoperative pain, pulp inflammation or necrosis. • Animal studies. • In vitro or ex vivo studies. • Non-randomized clinical trials. • Prospective and retrospective cohort studies. • Case–control studies. • Reviews, editorials, and letters. • Studies not evaluating TheraCal as a pulp-capping agent. Methodological quality and certainty of evidence The risk of bias in the included trials was independently assessed by at least two reviewers (M.M. and S.M. or R.W. and A.F.) using the Cochrane Risk of Bias 2 (ROB-2) tool. Any disagreements were resolved by consensus with a third reviewer (D.A.). The ROB-2 tool evaluates five domains: randomization process, deviations from intended interventions, outcome measurement, missing outcome data, and selective reporting. Overall judgments were categorized as low risk, some concerns, or high risk of bias. The certainty of the evidence was further appraised using the GRADE approach, which considers study limitations, inconsistency, indirectness, imprecision, and publication bias to provide an overall rating of confidence in the findings. Data extraction Data extraction was independently performed by at least two reviewers (M.M. and S.M. or R.W. and A.F.), with any disagreements resolved through consultation with a third reviewer (D.A.). Extracted data were recorded in a standardized Google Sheets form and included the following: Study and population characteristics Study and population characteristics Risk of bias assessments Risk of bias assessments Primary and secondary outcome data Primary and secondary outcome data Certainty of evidence The certainty of evidence was assessed using the GRADE framework for each pooled comparison included in the meta-analysis. Certainty ratings were determined according to risk of bias, inconsistency, indirectness and imprecision across the body of evidence contributing to each pooled estimate. A summary of findings table was constructed for outcomes: Success rates: Direct pulp capping with different comparisons and follow ups Success rates: Direct pulp capping with different comparisons and follow ups Success rates: Indirect pulp capping with different comparisons and follow ups Success rates: Indirect pulp capping with different comparisons and follow ups Statistical analysis All statistical analyses and graphical outputs were generated using RStudio with the meta package. Dichotomous outcomes were analyzed using the metabin function. A random-effects model was applied throughout to account for anticipated clinical and methodological heterogeneity among studies. Dichotomous outcomes were summarized using risk ratios (RRs) with 95% confidence intervals (CIs), estimated via the Mantel–Haenszel method. Statistical heterogeneity was assessed using the I² statistic and the Chi-square test, with higher I² values indicating greater heterogeneity. Publication bias was evaluated using funnel plots and Egger’s test when ≥ 10 studies were available [13]. Results Study inclusion A total of 606 records were identified through searches of four databases (PubMed, Web of Science, Scopus, and the Cochrane Library). After removal of duplicates (n = 320), 286 records were screened by title and abstract. Of these, 272 studies were excluded, and 14 full-text articles were assessed for eligibility. Ultimately, 11 studies met the inclusion criteria and were incorporated into this systematic review. The study selection process is illustrated in Fig. 1. Prisma flow chart for the included studies Study characteristics This review included 11 clinical studies published between 2015 and 2025, originating primarily from India, Turkey, Egypt, and the United States. The studies evaluated the clinical performance of TheraCal LC in direct pulp capping (DPC) and indirect pulp capping (IPC/IPT) procedures, with comparisons against calcium hydroxide-based materials and other bioactive calcium silicate materials such as Biodentine and MTA. Sample sizes ranged from 20 to 525 teeth/patients, with follow-up periods varying between 6 and 36 months. Most studies enrolled adult participants aged 15 to 45 years. The evaluated outcomes included clinical and radiographic success rates, pain assessment using the visual analogue scale (VAS), and dentin bridge or calcific barrier formation. Table 2 provides a detailed summary of the characteristics of the included studies. Also, the comparative success rates of TheraCal LC versus other pulp-capping materials are summarized in Table 3. Table 2Characteristics of included studiesStudy IDCountryAimSample SizeAge (mean ± SD)OutcomesFollow-Up (months)Control Group(s)Intervention GroupsConclusionAwadhesh (2025) [14]IndiaCompare TheraCal LC, Binar LC, CEM cement, and CH in IPC.52 patients (13/group)Range: 17–40 yearsPain (VAS), pulp vitality, radiographic PDL/periapical status.6 monthsCalcium Hydroxide (CH)CEM cement and TheraCal LCAll tested materials were effective IPC agents; however, bioactive materials (CEM cement and TheraCal LC) demonstrated superior clinical outcomes and sealing ability compared to traditional calcium hydroxide.Bayoumy (2021) [15]EgyptEvaluate TheraCal vs. CH in 2-step IPC.41 teeth analyzedRange: 15 + years (permanent teeth)Pain (VAS), bacterial reduction (S. mutans, Lactobacilli).12 monthsCalcium Hydroxide (Dycal)TheraCal LCBoth resin-modified calcium silicate (TheraCal LC) and calcium hydroxide (Dycal) are effective for relieving pain and reducing bacteria; however, TheraCal LC was significantly more effective at reducing pain at 12 months.Caliver (2024) [16]USAClinical comparison of three IPC protocols.90 teeth (30/group)-pain (VAS scale) and success rate12 monthsCalcium Hydroxide (Dycal)TheraCal LCThe success rate of indirect pulp capping therapy on permanent teeth was not affected by the pulp capping restorative protocol.Cengiz (2015) [17]TurkeyEvaluate Er, Cr: YSGG laser with TheraCal or CH in DPC*.60 teeth (15/group)28.0 ± (not specified); Range: 18–41Vitality, pain, thermal/percussion response, radiographs.6 monthsCalcium Hydroxide (Dycal)Laser-irradiated groups TheraCal and CHEr, Cr: YSGG laser irradiation at 0.5 W combined with pulp capping agents significantly improves success rates for direct pulp therapy; TheraCal and calcium hydroxide alone showed similar survival rates.Deshmukh (2024)[18]IndiaCompare RMGIC and TheraCal LC as IPC materials.31 teeth at final analysisMean: 29; Range: 18–40Pain (VAS), vitality, mobility, periapical changes.6 monthsRMGICTheraCal LCBoth RMGIC and TheraCal LC are effective IPC materials, though RMGIC showed a slight advantage in maintaining 100% pulp vitality and minimizing periapical changes over the 6-month period.Iyer (2021)[19]IndiaCompare TheraCal LC, Biodentine, and MTA Plus in DPC*.80 teeth analyzedRange: 15–45 yearsPain, vitality, radiographic dentin bridge formation.6 monthsMTA PlusTheraCal LC and BiodentineTheraCal LC, Biodentine, and MTA Plus are all potential agents for direct pulp capping (DPC) as there were no statistically significant differences in their success rates.Mahapatra (2022)[20]IndiaCompare light-cured CH and TheraCal LC in IPC.28 teeth (14/group)Range: 17–40 yearsPain, tenderness, sensibility, calcific barrier.6 monthsLight-cured CHTheraCal LC.TheraCal LC can be used as a predictable alternative to light-cured calcium hydroxide in IPC procedures for teeth with deep carious lesions.Abd El-Naby (2023)[3]EgyptEvaluate MTA and TheraCal LC as IPC materials.20 patients (10/group)Range: 17–35 yearsPain, tenderness, thermal test, PDL width, lesions.6 monthsProRoot MTATheraCal LCBoth MTA and TheraCal LC are favorable materials for IPC, showing similar clinical and radiographic outcomes with no significant difference between them.Peskersoy (2020)[21]TurkeyEffectiveness of calcium silicates vs. CH in DPC*.525 teeth (105/group)Range: 18–42 yearsClinical/radiographic success, PDL status, dentin bridge.36 monthsCH (Dycal)MTA+ Biodentine and TheraCal LCMTA + and Biodentine are the most appropriate materials for direct pulp capping long-term; TheraCal LC is a viable alternative to calcium hydroxide, though its filler ingredients may decrease its success rate relative to the other silicates.Rahman (2021)[22]IndiaCompare Biodentine, TheraCal LC, and Dycal in IPT.54 teeth analyzed12.36 ± 2.29Pain, sensitivity, PDL widening, root development.24 monthsDycal (CH)TheraCal LC and BiodentineTheraCal LC and Biodentine are superior to calcium hydroxide for indirect pulp therapy in young permanent teeth, showing significantly higher success rates at 24 months.Velioğlu (2021)[23]TurkeyCompare CH, Biodentine, MTA, and TheraCal LC in DPC*.94 patientsRange: 18–45 yearsSpontaneous pain, percussion, sensitivity, vitality.12 monthsCalcium HydroxideBiodentine and TheraCal LCAll four materials (Biodentine, MTA, TheraCal LC, and calcium hydroxide) provided sufficient and similar clinical success in preserving tooth vitality during short-term follow-up. Characteristics of included studies Deshmukh (2024) [18] Iyer (2021) [19] Mahapatra (2022) [20] Abd El-Naby (2023) [3] Peskersoy (2020) [21] Rahman (2021) [22] Velioğlu (2021) [23] Table 3Clinical success rates and success criteria used in the included studiesStudyYearComparisonTotal_interventionN_interventionTotal_controlN_controlTimeSuccess CriteriaDirect pulp cappingCengiz (2015) [17]2015Theracal vs. CH151015116 monthsMaintenance of vitality, absence of spontaneous pain, normal thermal/percussion response, and no radiographic changes.Peskersoy (2020)[21]202010587105816 monthsScore 1–2 success: Asymptomatic or slight cold sensitivity; no/slight PDL widening; and complete/partial dentin bridge.Peskersoy (2020)[21]2020105771057612 monthsVelioğlu (2021)[23]2021231826226 monthsNo pain, positive vitality, and no resorption, periradicular disease, PDL widening, fistula, or edema.Velioğlu (2021)[23]20212218252012 monthsIyer (2021)[19]2021Theracal vs. MTA272527246 monthsAsymptomatic status, positive sensibility response (Thermal/EPT), and no radiographic sign of periapical pathology.Peskersoy (2020)[21]202010587105906 monthsMentioned abovePeskersoy (2020)[21]2020105771059012 monthsVelioğlu (2021)[23]2021232025226 monthsMentioned aboveVelioğlu (2021)[23]20212218252112 monthsIyer (2021)[19]2021Theracal vs. Biodentine272527246 monthsMentioned abovePeskersoy (2020)[21]202010587105886 monthsMentioned abovePeskersoy (2020)[21]2020105771058412 monthsVelioğlu (2021)[23]2021231923206 monthsMentioned aboveVelioğlu (2021)[23]20212218222012 monthsIndirect pulp cappingRahman (2021)[22]2021191919193 monthsNo pain/sensitivity/mobility/inflammation and radiographic absence of resorption, widening, or lesions.Rahman (2021)[22]2021191919196 monthsRahman (2021)[22]20211919191812 monthsAwadhesh (2025) [14]2025Theracal vs. CEM131213136 monthsNo pain (VAS 0–10), no percussion tenderness, positive cold vitality test, and no radiographical periapical radiolucency or PDL widening.Awadhesh (2025) [14]2025131213126 monthsCaliver (2024) [16]20243029303012 monthsPulp vitality based on percussion, palpation, cold test, and radiographic findingsRahman (2021)[22]2021191919193 monthsMentioned aboveRahman (2021)[22]2021191919186 monthsRahman (2021)[22]20211919191712 monthsAwadhesh (2025) [14]2025Theracal vs. CH light-cured131213126 monthsMentioned aboveMahapatra (2022)[20]2022141314123 monthsPrimary: Presence of calcified barrier. Secondary: No pain/tenderness, positive sensibility, and no PDL widening/radiolucency.Mahapatra (2022)[20]2022141414136 monthsAbd El-Naby [3]2023Theracal vs. MTA1091093 monthsAbsence of spontaneous pain/tenderness/sinuses, positive thermal response, normal PDL width, and no periapical lesions.Abd El-Naby [3]20231091096 monthsCaliver (2024) [16]2024Theracal vs. No liner3029303012 monthsMentioned aboveDeshmukh (2024)[18]2024Theracal vs. RMGI231923236 monthsPreserved vitality, normal cold/electric tests, absence of pain/swelling/tenderness, and no periapical radiographic changes. Clinical success rates and success criteria used in the included studies Peskersoy (2020) [21] Peskersoy (2020) [21] Iyer (2021) [19] Peskersoy (2020) [21] Peskersoy (2020) [21] Iyer (2021) [19] Peskersoy (2020) [21] Peskersoy (2020) [21] Rahman (2021) [22] Rahman (2021) [22] Rahman (2021) [22] Rahman (2021) [22] Rahman (2021) [22] Rahman (2021) [22] Mahapatra (2022) [20] Mahapatra (2022) [20] Deshmukh (2024) [18] Success rate and criteria Across both direct and indirect pulp-capping procedures, TheraCal LC demonstrated consistently high clinical success rates, frequently comparable to calcium hydroxide, MTA, Biodentine, CEM cement, RMGI, and no-liner approaches. Although minor numerical differences were observed among materials at specific follow-up intervals, no consistent or clinically significant superiority was evident for any comparator. The detailed success rates and evaluation criteria are summarized in Table 3. Dentin bridge formation and pain score For pain outcomes, most studies reported low pain scores or absence of pain during follow-up periods ranging from 3 to 24 months. In several trials, including those by Bayoumy et al. and Mahapatra et al. [20, 15], pain scores in the TheraCal LC groups decreased progressively over time and reached nearly zero by 6 months. Comparable pain outcomes were observed between TheraCal LC and other bioactive materials such as MTA, Biodentine, CEM cement, and calcium hydroxide-based materials. However, some studies, including those by Velioğlu et al. and Abd El-Naby et al. [23, 3], reported slightly higher numbers of patients experiencing pain in the TheraCal LC groups compared with certain comparators. Detailed pain outcomes and dentin bridge formation data are provided in Supplemental Table S3. Quality assessment results Risk of bias was assessed for all eleven included studies using the Cochrane Collaboration ROB-2 tool, as illustrated in Fig. 2. The majority of studies were judged as presenting some concerns. Only one study, conducted by Bayoumy et al. [15], was rated as having an overall high risk of bias due to substantial concerns in the domain related to missing outcome data (D3). Conversely, one study [24] was assessed as low risk of bias across all domains. Risk of bias assessment (ROB 2) Most studies demonstrated low risk of bias in domains related to deviations from intended interventions (D2), measurement of outcomes (D4), and missing outcome data (D3). However, some concerns were frequently identified in the randomization process (D1) and selection of reported results (D5), primarily due to insufficient reporting of allocation concealment, random sequence generation, or lack of pre-registered protocols. Overall, the methodological quality of the included randomized clinical trials was considered acceptable. Nevertheless, caution is warranted when interpreting findings from studies with some concerns or high risk of bias. Figure 2 provides a summary of the risk of bias assessment results. Certainty of evidence (GRADE approach) The certainty of evidence for all comparisons evaluating the success rates of Theracal in both direct and indirect pulp capping procedures was assessed using the GRADE approach. Evidence originated from randomized controlled trials and was downgraded by one level for risk of bias due to methodological limitations in the included studies, while no concerns were identified regarding inconsistency, indirectness, imprecision, or other considerations. The certainty ratings and downgrading rationale are summarized in Table 4. Table 4Summarizes certainty of evidenceCertainty assessmentNo. of patientsEffectCertaintyImportanceNo. of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerations[Theracal][Other materials]Relative(95% CI)Absolute(95% CI)A. Success rates: Direct Pulp Capping (TheraCal VS Biodentine: Follow up 6 months)3Randomised trialsseriousnot seriousnot seriousnot seriousnone1551551 [0.91: 1.09]0 more per 1000 (95% CI 76 fewer to 76 more)⨁⨁⨁◯ModerateCRITICALB. Success rates: Direct Pulp Capping (TheraCal VS Biodentine: Follow up 12 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone1271270.91 [0.8: 1.04]67 more per 1000 (95% CI 150 fewer to 30 more)⨁⨁⨁◯ModerateCRITICALC. Success rates: Direct Pulp Capping (TheraCal VS Calcium Hydroxide: Follow up 6 months)3Randomised trialsseriousnot seriousnot seriousnot seriousnone1431461.03 [0.92: 1.16]24 less per 1000 (95% CI 64 fewer to 129 more)⨁⨁⨁◯ModerateCRITICALD. Success rates: Direct Pulp Capping (TheraCal VS Calcium Hydroxide: Follow up 12 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone1271301.02 [0.88: 1.17]15 less per 1000 (95% CI 90 fewer to 127 more)⨁⨁⨁◯ModerateCRITICALE. Success rates: Direct Pulp Capping (TheraCal VS MTA: Follow up 6 months)3Randomised trialsseriousnot seriousnot seriousnot seriousnone1551570.99 [0.91: 1.08]9 more per 1000 (95% CI 77 fewer to 68 more)⨁⨁⨁◯ModerateCRITICALF. Success rates: Direct Pulp Capping (TheraCal VS MTA: Follow up 12 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone1271300.88 [0.78: 1]90 more per 1000 (95% CI 97 fewer to 0 more)⨁⨁⨁◯ModerateCRITICALG. Success rates: Indirect Pulp Capping (TheraCal VS Calcium Hydroxide: Follow up 6 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone32321.04 [0.95: 1.15]39 less per 1000 (95% CI 48 fewer to 145 more)⨁⨁⨁◯ModerateCRITICALH. Success rates: Indirect Pulp Capping (TheraCal VS Calcium Hydroxide: Follow up 12 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone49491.02 [0.89: 1.17]20 less per 1000 (95% CI 108 fewer to 167 more)ModerateCRITICALI. Success rates: Indirect Pulp Capping (TheraCal VS Light-Cured Calcium Hydroxide: Follow up 6 months)2Randomised trialsseriousnot seriousnot seriousnot seriousnone27271.05 [0. 93: 1.18]48 less per 1000 (95% CI 67 fewer to 173 more)ModerateCRITICALCI confidence interval Summarizes certainty of evidence ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate ⨁⨁⨁◯ Moderate CI confidence interval Data analysis A meta-analysis was conducted to assess the success rate of TheraCal LC compared with MTA, calcium hydroxide, and Biodentine, with subgroup analyses performed according to follow-up periods. The included studies used slightly different operational definitions of “success,” all criteria reflected the same underlying clinical construct: maintenance of pulp vitality without clinical symptoms or radiographic evidence of pathology. Despite variability in wording and specific test combinations, all definitions converged on a single clinically meaningful endpoint: maintenance of pulp vitality without clinical symptoms or radiographic evidence of pathology. Therefore, pooling was considered appropriate under a common conceptual outcome framework, where differences represent variations in measurement approach rather than fundamentally distinct endpoints. The main results of the meta-analysis are presented in Figs. 3, 4, 5, 6 and 7. Forest plot of success rates for TheraCal LC versus Biodentine in direct pulp capping Forest plot showing the success rate of TheraCal compared to CH (DPC) Forest plot showing the success rate of TheraCal compared to MTA (DPC) Forest plot showing the success rate of TheraCal compared to CH (IPC) Forest plot showing the success rate of TheraCal compared to light cured CH (IPC) Sensitivity analyses were not performed because of the limited number of studies available for each pooled comparison. Because no pooled comparison included ≥ 10 studies, formal assessment of publication bias was not feasible.Follow-up periods were analyzed as independent time-point subgroups and were not pooled together within the same meta-analytic estimate, thereby avoiding double counting within individual comparisons. A) Direct Pulp Capping (DPC) TheraCal compared to BiodentineFollow up 6 months subgroup: three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 1.00; 95% CI: 0.91–1.09). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3.Follow-up: 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 0.91; 95% CI: 0.80–1.04). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. TheraCal compared to BiodentineFollow up 6 months subgroup: three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 1.00; 95% CI: 0.91–1.09). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3.Follow-up: 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 0.91; 95% CI: 0.80–1.04). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. Follow up 6 months subgroup: three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 1.00; 95% CI: 0.91–1.09). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. Follow up 6 months subgroup: three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 1.00; 95% CI: 0.91–1.09). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. Follow-up: 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 0.91; 95% CI: 0.80–1.04). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. Follow-up: 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with Biodentine in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and Biodentine (RR = 0.91; 95% CI: 0.80–1.04). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 3. 2.TheraCal compared to Calcium Hydroxide (CH)Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.03; 95% CI: 0.92–1.16). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.88–1.17). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. TheraCal compared to Calcium Hydroxide (CH)Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.03; 95% CI: 0.92–1.16). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.88–1.17). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.03; 95% CI: 0.92–1.16). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.03; 95% CI: 0.92–1.16). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.88–1.17). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.88–1.17). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 4. 3.TheraCal compared to MTAFollow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.99; 95% CI: 0.91–1.08). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.88; 95% CI: 0.78–1.00). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. TheraCal compared to MTAFollow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.99; 95% CI: 0.91–1.08). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.88; 95% CI: 0.78–1.00). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.99; 95% CI: 0.91–1.08). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. Follow up 6 months subgroup: Three studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.99; 95% CI: 0.91–1.08). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.88; 95% CI: 0.78–1.00). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with MTA in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and MTA (RR = 0.88; 95% CI: 0.78–1.00). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 5. B) Indirect pulp capping (IPC) TheraCal compared to CHFollow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with CH in the control group.Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.04; 95% CI: 0.95–1.15). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 6.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.89–1.17). However, unlike other comparisons, statistical heterogeneity was moderate to substantial (I² = 65.2%), suggesting variability in study outcomes. These findings are illustrated in Fig. 6. TheraCal compared to CHFollow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with CH in the control group.Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.04; 95% CI: 0.95–1.15). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 6.Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.89–1.17). However, unlike other comparisons, statistical heterogeneity was moderate to substantial (I² = 65.2%), suggesting variability in study outcomes. These findings are illustrated in Fig. 6. Follow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with CH in the control group. Follow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with CH in the control group. Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.04; 95% CI: 0.95–1.15). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 6. Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.04; 95% CI: 0.95–1.15). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 6. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.89–1.17). However, unlike other comparisons, statistical heterogeneity was moderate to substantial (I² = 65.2%), suggesting variability in study outcomes. These findings are illustrated in Fig. 6. Follow up 12 months subgroup: Two studies evaluated the success rate of direct pulp capping using TheraCal LC in the test group compared with calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and calcium hydroxide (RR = 1.02; 95% CI: 0.89–1.17). However, unlike other comparisons, statistical heterogeneity was moderate to substantial (I² = 65.2%), suggesting variability in study outcomes. These findings are illustrated in Fig. 6. 2.TheraCal LC compared with Light-Cured Calcium Hydroxide (CH) – Indirect Pulp CappingFollow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with Light cured CH in the control group.Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with light-cured calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and light-cured calcium hydroxide (RR = 1.05; 95% CI: 0.93–1.18). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 7.Publication Bias: Assessment of publication bias was not performed because fewer than ten studies were included in each meta-analysis. According to methodological recommendations, statistical methods for detecting publication bias, such as funnel plot asymmetry and Egger’s regression test, are considered unreliable when applied to a limited number of studies [13]. TheraCal LC compared with Light-Cured Calcium Hydroxide (CH) – Indirect Pulp CappingFollow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with Light cured CH in the control group.Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with light-cured calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and light-cured calcium hydroxide (RR = 1.05; 95% CI: 0.93–1.18). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 7.Publication Bias: Assessment of publication bias was not performed because fewer than ten studies were included in each meta-analysis. According to methodological recommendations, statistical methods for detecting publication bias, such as funnel plot asymmetry and Egger’s regression test, are considered unreliable when applied to a limited number of studies [13]. Follow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with Light cured CH in the control group. Follow up 3 months subgroup: Only one study evaluated the success rate of indirect pulp capping through the application of Theracal in the test group compared with Light cured CH in the control group. Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with light-cured calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and light-cured calcium hydroxide (RR = 1.05; 95% CI: 0.93–1.18). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 7. Follow up 6 months subgroup: Two studies evaluated the success rate of indirect pulp capping using TheraCal LC in the test group compared with light-cured calcium hydroxide in the control group. The pooled meta-analysis indicated no significant difference in success rates between TheraCal LC and light-cured calcium hydroxide (RR = 1.05; 95% CI: 0.93–1.18). Statistical heterogeneity was negligible (I² = 0%), as illustrated in Fig. 7. Publication Bias: Assessment of publication bias was not performed because fewer than ten studies were included in each meta-analysis. According to methodological recommendations, statistical methods for detecting publication bias, such as funnel plot asymmetry and Egger’s regression test, are considered unreliable when applied to a limited number of studies [13]. Publication Bias: Assessment of publication bias was not performed because fewer than ten studies were included in each meta-analysis. According to methodological recommendations, statistical methods for detecting publication bias, such as funnel plot asymmetry and Egger’s regression test, are considered unreliable when applied to a limited number of studies [13]. Discussion This systematic review and meta-analysis aimed to evaluate the clinical efficacy of TheraCal LC, a resin-modified calcium silicate material, for both direct and indirect pulp-capping procedures. Across the included studies, TheraCal LC consistently demonstrated high success rates comparable to established agents such as mineral trioxide aggregate (MTA) and calcium hydroxide [Ca(OH)₂]. Several factors appear to contribute to these favorable outcomes, including accurate clinical assessment of pulp vitality, meticulous removal of infected dentin, and achievement of a hermetic marginal seal that prevents microleakage and limits nutrient supply to residual cariogenic bacteria, thereby inhibiting further infection and inflammation [25, 26]. TheraCal LC’s effectiveness has been investigated across vital pulp therapy procedures in permanent teeth, including both direct pulp capping (DPC) and indirect pulp capping (IPC). Hydraulic calcium silicate cements are known to promote reparative dentinogenesis and support the dentin–pulp complex through localized biomineralization at the injury site [27]. Direct Pulp Capping (DPC) Comparisons between TheraCal LC and CH, MTA, and Biodentine consistently demonstrated high clinical success rates across all groups. In studies such as Peskersoy et al. [21], and Velioğlu et al. [23], TheraCal LC showed comparable or slightly superior outcomes to CH at both 6 and 12 months. When compared with MTA, TheraCal LC generally performed similarly, though some studies reported marginally higher long-term success with MTA. Comparisons with Biodentine revealed no major differences, with both materials maintaining stable success rates over time. When compared with MTA, TheraCal showed generally similar clinical performance. In the trial by Iyer et al. [19], success rates at 6 months were 92.6% for TheraCal and 88.9% for MTA. Comparable findings were also reported by Peskersoy et al. [21], and Velioğlu et al. [23], although some studies demonstrated marginally higher long-term success with MTA. Likewise, comparisons between TheraCal and Biodentine revealed no major differences in clinical success. Most included studies demonstrated high success rates for both materials, with outcomes remaining relatively stable over time. Although Biodentine occasionally showed numerically higher long-term success rates, the differences were generally small and clinically limited. Indirect Pulp Capping (IPC) TheraCal LC also demonstrated comparable success rates to CH, MTA, resin-modified glass ionomer (RMGI), CEM cement, and no-liner approaches. Rahman et al. [22] reported nearly complete success at 3 and 6 months, with only slight reductions at 12 months. Mahapatra et al. and Abd El-Naby et al. [3, 20] similarly found TheraCal LC comparable to CH and MTA. More recent studies, such as Caliver et al. [16]. and Deshmukh et al. [18], confirmed favorable outcomes, though occasional differences were noted against RMGI. Clinical trials focusing on mandibular molars emphasized the importance of precise operative technique, aseptic access, effective hemostasis, and durable sealing, as pivotal for success [28]. Despite anatomical complexity, TheraCal LC and MTA yielded comparable outcomes, supporting their applicability in challenging cases [3]. Mechanisms of action The efficacy of calcium silicate materials (CSMs) such as TheraCal LC derives from their bioactive properties, particularly stimulation of reparative dentin formation. TheraCal LC releases calcium (Ca²⁺) and hydroxide (OH⁻) ions, fostering hydroxyapatite precipitation and dentin bridge formation [3]. Notably, TheraCal LC has been shown to release higher levels of these ions than ProRoot MTA or Calcimol LC for up to 60 days [29]. Clinically, this corresponds with increased dentin density and reparative dentin quality compared to alternatives [30, 31]. Advantages and limitations TheraCal LC combines the bioactivity of calcium silicates with enhanced handling characteristics. Its resin-modified, light-cured formulation allows rapid polymerization and immediate restoration placement, reducing treatment time and contamination risk compared with MTA [3, 22]. The hydrophilic resin matrix enables sustained ion release, promoting dentinogenesis [3, 15, 30, 32]. However, limitations exist. In DPC, incomplete polymerization in deep cavities may lead to cytotoxic uncured monomer release, impairing pulp healing [3, 33]. Certain filler components may also inhibit cellular proliferation. These factors may explain why long-term outcomes sometimes approximate those of CH [21]. Success in IPC often depends more on restoration quality and coronal sealing than on the specific capping material [22, 26]. Adjunctive therapies, such as Er, Cr: YSGG laser irradiation, have shown promise in enhancing outcomes. One study [17] reported 100% six-month success when TheraCal LC or CH were combined with laser treatment, highlighting the potential of synergistic approaches. Limitations of evidence Despite a growing number of randomized controlled trials (RCTs) evaluating TheraCal LC as a pulp-capping material, the GRADE assessment revealed predominantly moderate-certainty evidence across all included studies. This rating was primarily influenced by risk-of-bias concerns identified in several included studies. Most studies had relatively short follow-up periods (6–12 months), highlighting the urgent need for longer-term randomized trials with histological assessments to confirm dentin quality and sustained pulp vitality, particularly in relation to the resin component of TheraCal LC. Overall, the evidence supports TheraCal LC and other calcium silicate materials (CSMs) as effective agents for indirect pulp capping, promoting robust dentinogenesis. For direct pulp capping in mature teeth, however, MTA and Biodentine typically demonstrate the most consistent long-term success. Clinical implications Clinicians may consider TheraCal LC a viable alternative for vital pulp therapy, particularly in indirect pulp capping procedures where rapid setting and ease of use are desirable. In direct pulp capping cases, awareness of its resin-modified nature and potential polymerization limitations is critical to optimize outcomes. Adjunctive techniques, such as laser irradiation, may further enhance clinical success and warrant consideration. Above all, meticulous clinical protocols, including accurate pulp vitality assessment and high-quality restorative sealing, remain essential determinants of treatment success. Future research To consolidate the clinical application of TheraCal LC and other calcium silicate materials, further randomized controlled trials with extended follow-up durations (beyond two years) are needed. Such studies should incorporate histological evaluations to clarify the quality and durability of reparative dentin formation. Investigations into improved polymerization techniques and material formulations that mitigate resin shrinkage effects will be valuable. Additionally, larger trials examining the efficacy of adjunctive treatments, including laser therapies and newer formulations such as TheraCal PT, will help refine optimal clinical protocols. Conclusions Despite variability in outcome definitions across included studies and relatively small sample sizes, TheraCal LC demonstrates high clinical efficacy as a bioactive pulp-capping material in both direct and indirect procedures in permanent dentition. Its resin-modified calcium silicate formulation combines favorable bioactivity with improved handling properties, facilitating rapid polymerization and effective dentin regeneration. TheraCal LC represents a reasonable alternative to MTA, calcium hydroxide, and Biodentine for vital pulp therapy. Nevertheless, current results should be interpreted with caution. Further well-designed randomized clinical trials with larger sample sizes and standardized outcome assessment criteria are required to strengthen the evidence base and confirm long-term outcomes. Supplementary Information Supplementary Material 1.